212 related articles for article (PubMed ID: 33751289)
1. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 2018.
Morgan A; Hartmanis S; Tsochatzis E; Newsome PN; Ryder SD; Elliott R; Floros L; Hall R; Higgins V; Stanley G; Cure S; Vasudevan S; Pezzullo L
Eur J Health Econ; 2021 Jun; 22(4):505-518. PubMed ID: 33751289
[TBL] [Abstract][Full Text] [Related]
2. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.
Schattenberg JM; Lazarus JV; Newsome PN; Serfaty L; Aghemo A; Augustin S; Tsochatzis E; de Ledinghen V; Bugianesi E; Romero-Gomez M; Bantel H; Ryder SD; Boursier J; Leroy V; Crespo J; Castera L; Floros L; Atella V; Mestre-Ferrandiz J; Elliott R; Kautz A; Morgan A; Hartmanis S; Vasudevan S; Pezzullo L; Trylesinski A; Cure S; Higgins V; Ratziu V
Liver Int; 2021 Jun; 41(6):1227-1242. PubMed ID: 33590598
[TBL] [Abstract][Full Text] [Related]
3. Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand.
Phisalprapa P; Prasitwarachot R; Kositamongkol C; Hengswat P; Srivanichakorn W; Washirasaksiri C; Treeprasertsuk S; Charatcharoenwitthaya P; Chaiyakunapruk N
BMC Gastroenterol; 2021 Mar; 21(1):135. PubMed ID: 33765931
[TBL] [Abstract][Full Text] [Related]
4. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
O'Hara J; Finnegan A; Dhillon H; Ruiz-Casas L; Pedra G; Franks B; Morgan G; Hebditch V; Jönsson B; Mabhala M; Reic T; Van Thiel I; Ratziu V; Romero-Gomez M; Bugianesi E; Schattenberg JM; Anstee QM
JHEP Rep; 2020 Oct; 2(5):100142. PubMed ID: 32775976
[TBL] [Abstract][Full Text] [Related]
5. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
Witkowski M; Moreno SI; Fernandes J; Johansen P; Augusto M; Nair S
Pharmacoeconomics; 2022 Aug; 40(8):751-776. PubMed ID: 35789987
[TBL] [Abstract][Full Text] [Related]
6. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
[TBL] [Abstract][Full Text] [Related]
7. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
[TBL] [Abstract][Full Text] [Related]
8. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
[TBL] [Abstract][Full Text] [Related]
9. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States.
Younossi ZM; Tampi R; Priyadarshini M; Nader F; Younossi IM; Racila A
Hepatology; 2019 Feb; 69(2):564-572. PubMed ID: 30180285
[TBL] [Abstract][Full Text] [Related]
10. Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: Data from Hong Kong.
Tampi RP; Wong VW; Wong GL; Shu SS; Chan HL; Fung J; Stepanova M; Younossi ZM
Hepatol Res; 2020 Sep; 50(9):1024-1031. PubMed ID: 32537840
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait.
Sanai FM; Al Khathlan A; Al Fadhli A; Jazzar AS; Hashim AM; Mansour E; Abaalkhail F; Hasan F; Al Mudaiheem H; Al Quraishi H; Bottomley J; Alswat KA; Al Ghamdi M; Farghaly M; Fathy M; Awad N; Mohamed O; Kozma S; Al-Hamoudi W; Al-Jedai A
Hepatol Int; 2021 Aug; 15(4):912-921. PubMed ID: 33822317
[TBL] [Abstract][Full Text] [Related]
13. Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies.
Golabi P; Owrangi S; Younossi ZM
Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S1-S9. PubMed ID: 38813821
[TBL] [Abstract][Full Text] [Related]
14. A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH).
Povsic M; Wong OY; Perry R; Bottomley J
Adv Ther; 2019 Jul; 36(7):1574-1594. PubMed ID: 31065991
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database.
Shelley K; Articolo A; Luthra R; Charlton M
BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis.
McSweeney L; Breckons M; Fattakhova G; Oluboyede Y; Vale L; Ternent L; Balp MM; Doward L; Brass CA; Beyer F; Sanyal A; Anstee QM
JHEP Rep; 2020 Jun; 2(3):100099. PubMed ID: 32435754
[TBL] [Abstract][Full Text] [Related]
17. Societal costs and survival of patients with biopsy-verified non-alcoholic steatohepatitis: Danish nationwide register-based study.
Rudolfsen JH; Gluud LL; Grønbæk H; Jensen MK; Vyberg M; Olsen J; Bo Poulsen P; Hovelsø N; Gregersen NT; Thomsen AB; Jepsen P
Ann Hepatol; 2024; 29(3):101285. PubMed ID: 38272183
[TBL] [Abstract][Full Text] [Related]
18. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.
Johansen P; Howard D; Bishop R; Moreno SI; Buchholtz K
Pharmacoeconomics; 2020 May; 38(5):485-497. PubMed ID: 31919793
[TBL] [Abstract][Full Text] [Related]
19. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
[TBL] [Abstract][Full Text] [Related]
20. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
